Novartis to acquire dry eye drug lifitegrast
- Posted on: May 13 2019
- Leave a response
The prescription dry eye treatment lifitegrast (Xiidra) will change hands from Takeda to Novartis later this year, at an estimated cost of $5.3 billion.
Source: AAO
Posted in: Uncategorized